Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Objective: This trial followed a structured nationwide training program in minimally invasive
distal pancreatectomy (MIDP), according to the IDEAL framework for surgical innovation …

This manuscript is the result of the North American Neuroendocrine Tumor Society
consensus conference on the surgical management of pancreatic neuroendocrine tumors …

Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an
autosomal dominant pattern, is continuing to raise great interest for endocrinology …

Objective: To compare perioperative outcomes of pancreatoduodenectomy (PD) performed
through the laparoscopic route or by open surgery. Summary Background Data …

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Background The oncological safety of minimally invasive surgery has been questioned for
several abdominal cancers. Concerns also exist regarding the use of minimally invasive …

Background The role of minimally invasive distal pancreatectomy is still unclear, and
whether robotic distal pancreatectomy (RDP) offers benefits over laparoscopic distal …

Background Risk factors for the development of clinically relevant POPF (CR-POPF)
following distal pancreatectomy (DP) need clarification particularly following the 2016 …